JP2023524912A - ４’－チオ－５－アザ－２’－デオキシシチジンを使用して血液がんを治療するための組成物及びその使用 - Google Patents

４’－チオ－５－アザ－２’－デオキシシチジンを使用して血液がんを治療するための組成物及びその使用 Download PDF

Info

Publication number
JP2023524912A
JP2023524912A JP2023509462A JP2023509462A JP2023524912A JP 2023524912 A JP2023524912 A JP 2023524912A JP 2023509462 A JP2023509462 A JP 2023509462A JP 2023509462 A JP2023509462 A JP 2023509462A JP 2023524912 A JP2023524912 A JP 2023524912A
Authority
JP
Japan
Prior art keywords
effective amount
days
administration
administering
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023509462A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021216936A5 (https=
JP2023524912A5 (https=
Inventor
マーク ジェイ スト
レベッカ ブーヘイカー
ドゥ ヨン チョン
ジン ス リ
ヒョニョン チョ
Original Assignee
サウザーン リサーチ インスチチュート
ピノットバイオ，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サウザーン リサーチ インスチチュート, ピノットバイオ，インコーポレイテッド filed Critical サウザーン リサーチ インスチチュート
Publication of JP2023524912A publication Critical patent/JP2023524912A/ja
Publication of JPWO2021216936A5 publication Critical patent/JPWO2021216936A5/ja
Publication of JP2023524912A5 publication Critical patent/JP2023524912A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023509462A 2020-04-23 2021-04-22 ４’－チオ－５－アザ－２’－デオキシシチジンを使用して血液がんを治療するための組成物及びその使用 Pending JP2023524912A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063014346P 2020-04-23 2020-04-23
US63/014,346 2020-04-23
PCT/US2021/028726 WO2021216936A1 (en) 2020-04-23 2021-04-22 Composition for treating blood cancer using 4'-thio-5-aza-2'-deoxycytidine and uses thereof

Publications (3)

Publication Number Publication Date
JP2023524912A true JP2023524912A (ja) 2023-06-13
JPWO2021216936A5 JPWO2021216936A5 (https=) 2024-05-01
JP2023524912A5 JP2023524912A5 (https=) 2024-05-01

Family

ID=78221459

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023509462A Pending JP2023524912A (ja) 2020-04-23 2021-04-22 ４’－チオ－５－アザ－２’－デオキシシチジンを使用して血液がんを治療するための組成物及びその使用

Country Status (8)

Country Link
US (2) US12208112B2 (https=)
EP (1) EP4138843A4 (https=)
JP (1) JP2023524912A (https=)
KR (1) KR20230004768A (https=)
CN (1) CN115768432A (https=)
AU (1) AU2021260964A1 (https=)
CA (1) CA3176543A1 (https=)
WO (1) WO2021216936A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3097003A1 (en) * 2018-04-19 2019-10-24 Southern Research Institute 4'-thio-nucleotide and -nucleoside prodrugs for the treatment of cancer
KR20240108406A (ko) 2021-10-19 2024-07-09 아키라바이오, 인크. 2'-데옥시시티딘 유사체를 포함하는 조성물 및 겸상 적혈구 질환, 지중해빈혈, 및 암의 치료를 위한 그의 용도
WO2024191252A1 (ko) * 2023-03-14 2024-09-19 주식회사 피노바이오 골수에 작용하는 5-아자-4'-티오-2'-데옥시사이티딘의 최고 혈중농도를 정교하게 제어가능한 경구용 제형
CN117187391B (zh) * 2023-09-15 2025-03-18 中国医学科学院北京协和医院 普卡霉素在垂体促肾上腺皮质激素腺瘤中的应用
WO2025100762A1 (ko) * 2023-11-08 2025-05-15 한국생명공학연구원 4'-티오-5-아자-2'-디옥시사이티딘을 포함하는 간질환의 개선, 예방 또는 치료용 조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019204637A1 (en) * 2018-04-19 2019-10-24 Southern Research Institute 4'-thio-nucleotide and -nucleoside prodrugs for the treatment of cancer

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020322A (en) 1993-11-09 2000-02-01 Pro-Neuron, Inc. Acyl deoxyribonucleoside derivatives and uses thereof
US5591722A (en) 1989-09-15 1997-01-07 Southern Research Institute 2'-deoxy-4'-thioribonucleosides and their antiviral activity
ES2402799T3 (es) 1998-07-23 2013-05-09 Southern Research Institute Prepreparación de compuestos de tioarabinofuranosilo y utilización de los mismos
WO2004018494A1 (ja) 2002-08-22 2004-03-04 Geneticlab Co., Ltd. ４’−チオヌクレオチド
US20060014949A1 (en) 2004-07-13 2006-01-19 Supergen Inc. Compositions and formulations of decitabine polymorphs and methods of use thereof
KR101125932B1 (ko) 2006-12-06 2012-03-22 아이디유엔 파마슈티칼즈, 인코포레이티드 (3ｓ)-3-［ｎ-(ｎ'-(2-ｔｅｒｔ-부틸페닐)옥사밀)알라니닐］아미노-5-(2',3',5',6'-테트라플루오로페녹시)-4-옥소펜탄산의 결정 형태
EP3782612B1 (en) 2008-05-15 2023-11-08 Celgene Corporation Oral formulations of cytidine analogs and methods of use thereof
WO2011109383A1 (en) 2010-03-02 2011-09-09 Southern Research Institute Use of 2'-deoxy -4'-thiocytidine and its analogues as dna hypomethylating anticancer agents
US20110218170A1 (en) * 2010-03-02 2011-09-08 Southern Research Institute Use of 2'-deoxy-4'-thiocytidine and its analogues as dna hypomethylating anticancer agents
WO2011109012A1 (en) * 2010-03-02 2011-09-09 Southern Research Institute Use of 2'-deoxy-4'-thiocytidine and its analogues as dna hypomethylating anticancer agents
BR112016028641A2 (pt) * 2014-07-14 2017-08-22 Gilead Sciences Inc ?método para tratar câncer?
TWI678373B (zh) 2014-10-31 2019-12-01 日商富士軟片股份有限公司 硫代核苷衍生物或其鹽及醫藥組合物
US10662214B2 (en) 2015-04-03 2020-05-26 Sichuan Keiun-Biotech Biopharmaceutical Co., Ltd. Compound of 4′-thionucleoside, as well as preparation method therefor, pharmaceutical composition thereof and application thereof
US20160312261A1 (en) 2015-04-24 2016-10-27 Plasmia Biotech, S.L. Enzymatic production of cytosinic nucleoside analogues
HK1252245A1 (zh) 2015-05-27 2019-05-24 Idenix Pharmaceuticals Llc 用於治疗癌症的核苷酸
EP3207932A1 (en) * 2016-02-19 2017-08-23 Universität Stuttgart Dna methyltransferase inhibitors for rett syndrome therapy
US20190240210A1 (en) * 2016-10-17 2019-08-08 Daiichi Sankyo Company, Limited Treatment Method by Combined Use of MDM2 Inhibitor and DNA Methyltransferase Inhibitor
JP7425734B2 (ja) 2018-02-01 2024-01-31 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ ２’－デオキシヌクレオシドを製造するための立体選択的合成およびプロセス
JP7520822B2 (ja) 2018-09-25 2024-07-23 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ ２’－ハロゲン化－４’－チオ－２’－デオキシ－５－アザシチジンアナログおよびその使用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019204637A1 (en) * 2018-04-19 2019-10-24 Southern Research Institute 4'-thio-nucleotide and -nucleoside prodrugs for the treatment of cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CANCER RESEARCH, vol. Vol.76, No.14, Suppl., JPN6025015872, 2016, pages 4722, ISSN: 0005710767 *
JOURNAL OF CLINICAL ONCOLOGY, vol. Vol.37, No.15, Suppl., JPN6025015874, 2019, ISSN: 0005710769 *
MOL CANCER THER, vol. Vol.17, No.1, Suppl., JPN6025015873, 2018, pages 12, ISSN: 0005710768 *

Also Published As

Publication number Publication date
WO2021216936A1 (en) 2021-10-28
US20250082662A1 (en) 2025-03-13
KR20230004768A (ko) 2023-01-06
AU2021260964A1 (en) 2022-12-01
US12208112B2 (en) 2025-01-28
EP4138843A1 (en) 2023-03-01
US20210330689A1 (en) 2021-10-28
CN115768432A (zh) 2023-03-07
EP4138843A4 (en) 2024-07-10
CA3176543A1 (en) 2021-10-28

Similar Documents

Publication Publication Date Title
JP2023524912A (ja) ４’－チオ－５－アザ－２’－デオキシシチジンを使用して血液がんを治療するための組成物及びその使用
DE60223670T2 (de) Fettsäuren als Faktoren für das Überleben und die Aktivierung von Neutrophilen.
EP1244456B1 (en) A pyrrolidineacetamide derivative for treatment of chronic or neuropathic pain
EP3662909A1 (en) Gamma secretase modulators for the treatment of immune system dysfunction
US7396819B2 (en) Anthelmintic formulations
JPWO2014038630A1 (ja) セシウム排泄剤、有害金属排泄剤、飲食品、飼料および医薬品
US20140274937A1 (en) Methods of treating hematologic cancers
BG107038A (bg) Гелен паразитициден състав
EP2015743A2 (de) Glutadon
CN101528251B (zh) 用于预防和治疗糖尿病性周围神经病变的含有g-csf的治疗剂
Shaw Suspected infection in children with cancer
CN1379676A (zh) 血浆代用品组合物
DE60215051T2 (de) Zusammensetzung und verfahren zur behandlung chronischer allograft-abstossung
EP0238207A1 (en) Bactericidal mixtures
EP1944037B1 (en) Remedy for mastitis
WO2025231221A1 (en) Long-acting injectable formulation for use in the treatment and prevention of leishmaniasis in humans and animals
EP0885609A1 (en) Use of a pharmaceutical composition in the treatment of traumatic arthritis in horses
US20090163442A1 (en) Treatment of cancer with 2-deoxygalactose
CN114728004A (zh) 用于治疗恶性血液病的组合疗法
Hohenhaus How I manage chemotherapy toxicity.
HK40031928A (en) Gamma secretase modulators for the treatment of immune system dysfunction
Behm et al. 883 Chronic lymphocytic leukemia (CLL) in a child
Gear Practical update on canine lymphoma: 2. Treatment
Biggar et al. 885 KINETIC DIFFERENCES BETWEEN MATURE AND IMMATURE BLOOD NEUTROPHILS
EP2049125A2 (en) Treatment of cancer with 2-deoxygalactose

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240419

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240419

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250421

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250425

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250718

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251020